STOCK TITAN

Prothena Announces Appointment of Hideki Garren, MD, PhD, as Chief Medical Officer

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
management
Rhea-AI Summary

Prothena Corporation announces the appointment of Dr. Hideki Garren as Chief Medical Officer, effective April 5, 2021. Dr. Garren will lead the company's clinical programs in neurology and rare diseases, leveraging his extensive experience from Roche and Novartis. His expertise in advancing late-stage development programs aligns with Prothena's transition to a fully integrated R&D and commercial enterprise. The company aims to enhance its pipeline targeting serious conditions like AL amyloidosis and Alzheimer’s disease, positioning itself for significant growth in the biotechnology sector.

Positive
  • Appointment of Dr. Hideki Garren as Chief Medical Officer could strengthen leadership and strategic direction in clinical programs.
  • Dr. Garren's track record in late-stage development is expected to advance Prothena’s clinical pipeline effectively.
Negative
  • Transitioning to a fully integrated business may pose challenges in operational continuity.
  • Potential experience gaps due to management change could impact ongoing projects.

Dr. Garren’s extensive expertise and successful track record of advancing neurology and rare disease programs through late-stage development, registration and launch supports Company’s transition to a fully-integrated R&D and commercial business

DUBLIN, Ireland, April 05, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today announced the appointment of Hideki Garren, MD, PhD, as Chief Medical Officer. Dr. Garren will lead the clinical and medical organizations to advance Prothena’s clinical pipeline.

“Hideki brings valuable experience and expertise to our team as we look ahead towards transitioning to a fully integrated research, development and commercial biotechnology company,” said Gene Kinney, PhD, President and Chief Executive Officer. “His experience leading several late-stage development programs in neurology and rare disease indications through registration and launch is particularly relevant as we advance our pipeline of programs in these areas. We are delighted to welcome him to the team as we prepare for our next stage of growth.”

“Prothena’s impressive scientific platform has advanced a rich pipeline of potentially transformational therapeutics, including several programs that have demonstrated benefit on meaningful clinical endpoints in diseases with highly significant unmet medical needs,” commented Dr. Garren. “I am excited to join the company during this dynamic period of growth and look forward to working as part of this exceptional team with a rich scientific heritage.”

Dr. Garren joins Prothena from F. Hoffmann-La Roche Ltd. (Roche) & Genentech Inc. where he was Vice President, Global Head of Neuroimmunology, leading Roche’s Neuroimmunology franchise team. A neurologist by training, Dr. Garren was most recently responsible for the Phase 3 clinical programs for Ocrevus for Multiple Sclerosis and Enspryng for Neuromyelitis Optica Spectrum Disorder. Dr. Garren also held the role of Executive Director, Translational Medicine Expert in Neuroscience with Novartis Pharma. Prior to Novartis, Dr. Garren served as Co-Founder, Executive Vice President, Chief Scientific Officer, and Chief Operating Officer of Bayhill Therapeutics, Inc., a company he started in 2002 based on a technology platform he co-invented while at Stanford University.

Dr. Garren earned his Bachelor of Science from the California Institute of Technology and his MD and PhD from the University of California, Los Angeles (UCLA). He completed his internship in internal medicine at UCLA, and his residency in neurology and fellowship in neuroimmunology at Stanford University.

About Prothena

Prothena Corporation plc is a late-stage clinical company with expertise in protein dysregulation and a pipeline of novel investigational therapeutics with the potential to change the course of devastating rare peripheral amyloid and neurodegenerative diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a number of other neurodegenerative diseases.

Contacts:

Media
Ellen Rose, Head of Communications
650-922-2405, ellen.rose@prothena.com

Investors
Jennifer Zibuda, Director, Investor Relations & Communications
650-837-8535, jennifer.zibuda@prothena.com


FAQ

Who is the new Chief Medical Officer of Prothena Corporation?

Dr. Hideki Garren has been appointed as the Chief Medical Officer of Prothena Corporation effective April 5, 2021.

What is Dr. Garren's experience before joining Prothena?

Dr. Garren previously served as Vice President, Global Head of Neuroimmunology at Roche and was responsible for Phase 3 clinical programs for Multiple Sclerosis and other neurological disorders.

What impact does Dr. Garren's appointment have on Prothena Corporation?

His leadership is expected to enhance Prothena’s capabilities in advancing its clinical pipeline and transitioning to a fully integrated R&D and commercial company.

Prothena Corporation plc Ordinary Shares

NASDAQ:PRTA

PRTA Rankings

PRTA Latest News

PRTA Stock Data

803.89M
53.77M
12.42%
95.81%
12.62%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
DUBLIN 2